Icure Pharmaceutical Incorporation Total Liabilities
Icure Pharmaceutical Incorporation total liabilities. Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has total liabilities worth ₩80.55 Billion KRW (≈ $54.59 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Icure Pharmaceutical Incorporation to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Icure Pharmaceutical Incorporation (2015–2024)
Total liabilities of Icure Pharmaceutical Incorporation from 2015 to 2024. This chart illustrates how Icure Pharmaceutical Incorporation's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Icure Pharmaceutical Incorporation's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Icure Pharmaceutical Incorporation Competitors by Total Liabilities
The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cryomax Cooling System Corp
TW:1587
|
Taiwan | NT$2.00 Billion |
|
Yenher Holdings Bhd
KLSE:5300
|
Malaysia | RM42.25 Million |
|
American Creek Resources Ltd
V:AMK
|
Canada | CA$30.45K |
|
ONDINE BIOMEDICAL INC.CDI
F:VF5
|
Germany | €5.95 Million |
|
Lithium Ionic Corp
V:LTH
|
Canada | CA$39.47 Million |
|
Playstudios Inc
NASDAQ:MYPS
|
USA | $60.23 Million |
|
Melhus Sparebank
OL:MELG
|
Norway | Nkr10.35 Billion |
|
Ailleron S.A.
WAR:ALL
|
Poland | zł299.94 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Icure Pharmaceutical Incorporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Icure Pharmaceutical Incorporation assets under control.
Liquidity & Leverage Metrics
Icure Pharmaceutical Incorporation Total Liabilities Ratios Explained
Icure Pharmaceutical Incorporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Icure Pharmaceutical Incorporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Icure Pharmaceutical Incorporation (2015–2024)
The table below shows the annual total liabilities of Icure Pharmaceutical Incorporation from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩72.62 Billion ≈ $49.22 Million |
-31.84% |
| 2023-12-31 | ₩106.54 Billion ≈ $72.20 Million |
-20.76% |
| 2022-12-31 | ₩134.45 Billion ≈ $91.11 Million |
+12.33% |
| 2021-12-31 | ₩119.69 Billion ≈ $81.11 Million |
+44.22% |
| 2020-12-31 | ₩82.99 Billion ≈ $56.24 Million |
-29.82% |
| 2019-12-31 | ₩118.27 Billion ≈ $80.15 Million |
+225.73% |
| 2018-12-31 | ₩36.31 Billion ≈ $24.61 Million |
-0.32% |
| 2017-12-31 | ₩36.43 Billion ≈ $24.69 Million |
+149.76% |
| 2016-12-31 | ₩14.58 Billion ≈ $9.88 Million |
-27.76% |
| 2015-12-31 | ₩20.19 Billion ≈ $13.68 Million |
-- |
About Icure Pharmaceutical Incorporation
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides … Read more